Literature DB >> 28734147

Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.

Teresa Deinlein1, Sigurd F Lax2, Thomas Schwarz3, Roberta Giuffrida1, Karin Schmid-Zalaudek4, Iris Zalaudek5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28734147     DOI： 10.1016/j.ejca.2017.06.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  12 in total

1.  Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.

Authors:  Angela Steineck; Niklas Krumm; Jay F Sarthy; Colin C Pritchard; Teresa Chapman; Andrew W Stacey; Nicholas A Vitanza; Bonnie Cole
Journal:  JCO Precis Oncol       Date:  2019-09-20

Review 2.  Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Authors:  Dai Ogata; Tetsuya Tsuchida
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 3.  Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response.

Authors:  Enrico Zelin; Carlo Alberto Maronese; Arianna Dri; Ludovica Toffoli; Nicola Di Meo; Gianluca Nazzaro; Iris Zalaudek
Journal:  J Clin Med       Date:  2022-06-11       Impact factor: 4.964

Review 4.  DNA repair defects and implications for immunotherapy.

Authors:  Katherine M Bever; Dung T Le
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

5.  Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab.

Authors:  Alessandra Chen; Nabilah Ali; Peter Boasberg; Allen S Ho
Journal:  J Clin Med       Date:  2018-01-10       Impact factor: 4.241

Review 6.  Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma.

Authors:  Teruki Yanagi; Shinya Kitamura; Hiroo Hata
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

7.  Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.

Authors:  Sophie Momen; Hiva Fassihi; Helen R Davies; Christos Nikolaou; Andrea Degasperi; Catherine M Stefanato; Joao M L Dias; Dhruba Dasgupta; Emma Craythorne; Robert Sarkany; Sophie Papa; Serena Nik-Zainal
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-10-23

Review 8.  Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Authors:  Anja Wessely; Theresa Steeb; Ulrike Leiter; Claus Garbe; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

9.  Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.

Authors:  Marco Rubatto; Martina Merli; Gianluca Avallone; Andrea Agostini; Luca Mastorino; Virginia Caliendo; Amelia Barcellini; Viviana Vitolo; Francesca Valvo; Maria Teresa Fierro; Simone Ribero; Pietro Quaglino
Journal:  Oncotarget       Date:  2021-05-25

10.  Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.

Authors:  Mahlatse C M Kgokolo; Katherine Anderson; Shalate C Siwele; Helen C Steel; Luyanda L I Kwofie; Mike M Sathekge; Pieter W A Meyer; Bernardo L Rapoport; Ronald Anderson
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.